title: Treatment of FSGS in Children.
abstract: Focal segmental glomerulosclerosis (FSGS) is a pathologic condition that represents many disease entities. The goals of therapy are to cure the disease. When this is not possible, the secondary goals are to reduce proteinuria to avoid the complications of nephrotic syndrome and to delay progression of kidney disease. Proteinuria remission is one of the most important independent predictors of kidney survival. Children with FSGS who do not achieve partial or complete remission have a 50% risk of progression to ESRD within 5 years whereas those who enter complete remission have a 5-year kidney survival rate of 90%. Treatment of idiopathic FSGS commonly involves immune-based and nonimmunologic therapy options. This manuscript will review the current state of FSGS therapy for children.
authors.affiliation: Department of Pediatrics, Cohen Children's Medical Center of New York, New York, NY; and Department of Pediatrics, University of Michigan, Ann Arbor, MI.
authors.forename: Christine B
authors.initials: CB
authors.lastname: Sethna
authors.affiliation: Department of Pediatrics, Cohen Children's Medical Center of New York, New York, NY; and Department of Pediatrics, University of Michigan, Ann Arbor, MI. Electronic address: dgipson@umich.edu.
authors.forename: Debbie S
authors.initials: DS
authors.lastname: Gipson
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D002648:Child; D016572:Cyclosporine / Q000627:therapeutic use; D005923:Glomerulosclerosis, Focal Segmental / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy*; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D009173:Mycophenolic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D009765:Obesity / Q000150:complications / Q000628:therapy; D000069283:Rituximab; D016559:Tacrolimus / Q000627:therapeutic use; D016896:Treatment Outcome; D014808:Vitamin D Deficiency / Q000150:complications / Q000188:drug therapy*
chemical_list: D000305:Adrenal Cortex Hormones; D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D058846:Antibodies, Monoclonal, Murine-Derived; D000959:Antihypertensive Agents; D007166:Immunosuppressive Agents; D000069283:Rituximab; D016572:Cyclosporine; D009173:Mycophenolic Acid; D016559:Tacrolimus
keywords: Child; FSGS; Nephrotic syndrome; Therapy